Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Next Previous
Trial Profile

A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 945237 (Primary) ; Linezolid; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Gram-positive infections; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Skin and soft tissue infections; Tuberculosis; Vancomycin-resistant enterococcal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 21 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment as per ClinicalTrials.gov record.
  • 13 May 2011 Planned end date changed from 1 Jul 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
  • 13 May 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top